Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-12-30

Clinical Trial Update: Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib [Phase 4]

View source ↗

Summary

A Phase IV randomized trial evaluating sustained sorafenib treatment in renal cell carcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sorafenib (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Renal Cell | Phase 4 | Status: TERMINATED